source
- PDS halts work on phase 3 cancer therapy to focus on colorectal contenderPDS Biotechnology has called time on its phase 3 head and neck cancer therapy to channel resources to a drug in phase 2 development for metastatic colorectal cancer.Fierce Biotech · 6h ago↗ source
- PTC’s $211M bid wins Sangamo auction, teeing up ‘special opportunity’ to enter Fabry marketPTC Therapeutics has struck a deal to buy Sangamo Therapeutics’ Fabry disease program for $111 million upfront, outbidding Astellas and TerSera Therapeutics for the near-approval gene therapy. Sang…Fierce Biotech · 8h ago↗ source
- Cullinan tees up J&J fight—and $100M payday—as Taiho-partnered drug hits phase 3 cancer goalTaiho Pharmaceutical and Cullinan Therapeutics have celebrated a second phase 3 victory for their small-molecule EGFR inhibitor, teeing up the partners to challenge Johnson & Johnson in a lung canc…